MAP2K7 and melanoma: Several lines of evidence indicate that the capacity of melanoma persister cells to tolerate BRAF/MEK inhibition relies in large part on the reprogramming of the cell biosynthetic processes, including mRNA translation and/or mitochondrial energy production [8].